Gilder Gagnon Howe & Co. LLC reduced its position in shares of NxStage Medical Inc. (NASDAQ:NXTM) by 0.5% during the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 6,018,076 shares of the medical device company’s stock after selling 29,938 shares during the period. NxStage Medical accounts for approximately 2.6% of Gilder Gagnon Howe & Co. LLC’s investment portfolio, making the stock its 5th largest position. Gilder Gagnon Howe & Co. LLC owned approximately 9.35% of NxStage Medical worth $130,472,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently made changes to their positions in NXTM. Bank of Montreal Can purchased a new position in shares of NxStage Medical during the second quarter worth $14,911,000. HBK Investments L P boosted its position in shares of NxStage Medical by 86.6% in the first quarter. HBK Investments L P now owns 63,100 shares of the medical device company’s stock worth $946,000 after buying an additional 29,291 shares in the last quarter. Deerfield Management Co. boosted its position in shares of NxStage Medical by 20.0% in the first quarter. Deerfield Management Co. now owns 5,506,028 shares of the medical device company’s stock worth $82,535,000 after buying an additional 917,028 shares in the last quarter. Nuveen Asset Management LLC boosted its position in shares of NxStage Medical by 11.2% in the first quarter. Nuveen Asset Management LLC now owns 336,055 shares of the medical device company’s stock worth $5,037,000 after buying an additional 33,974 shares in the last quarter. Finally, Menta Capital LLC purchased a new position in shares of NxStage Medical during the first quarter worth $552,000. Institutional investors and hedge funds own 98.26% of the company’s stock.

Institutional Ownership by Quarter for NxStage Medical (NASDAQ:NXTM)

Shares of NxStage Medical Inc. (NASDAQ:NXTM) traded down 0.687% during mid-day trading on Wednesday, reaching $23.855. The company’s stock had a trading volume of 36,180 shares. The company’s market capitalization is $1.54 billion. NxStage Medical Inc. has a 52-week low of $13.49 and a 52-week high of $26.07. The firm’s 50 day moving average is $24.07 and its 200-day moving average is $20.96.

NxStage Medical (NASDAQ:NXTM) last announced its earnings results on Thursday, August 4th. The medical device company reported ($0.03) earnings per share for the quarter, beating the consensus estimate of ($0.04) by $0.01. NxStage Medical had a negative return on equity of 3.79% and a negative net margin of 2.06%. The firm earned $92.20 million during the quarter, compared to the consensus estimate of $89.44 million. During the same quarter in the prior year, the company earned ($0.08) EPS. The firm’s revenue for the quarter was up 14.8% compared to the same quarter last year. Analysts forecast that NxStage Medical Inc. will post ($0.12) EPS for the current year.

A number of research analysts have recently weighed in on NXTM shares. Northland Securities set a $25.00 price target on NxStage Medical and gave the company a “buy” rating in a research report on Thursday, September 15th. Zacks Investment Research upgraded NxStage Medical from a “hold” rating to a “buy” rating and set a $24.00 price target for the company in a research report on Wednesday, July 6th. Jefferies Group lifted their price objective on NxStage Medical from $24.00 to $27.00 and gave the stock a “buy” rating in a research report on Friday, August 5th. Canaccord Genuity lifted their price objective on NxStage Medical from $22.00 to $26.00 and gave the stock a “buy” rating in a research report on Tuesday, August 2nd. Finally, BTIG Research reiterated a “buy” rating and set a $29.00 price objective on shares of NxStage Medical in a research report on Sunday, August 7th. One analyst has rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $26.43.

In other NxStage Medical news, Director Craig W. Moore sold 3,000 shares of the firm’s stock in a transaction that occurred on Wednesday, September 14th. The stock was sold at an average price of $23.31, for a total value of $69,930.00. Following the completion of the sale, the director now owns 90,739 shares in the company, valued at approximately $2,115,126.09. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Corporate insiders own 4.70% of the company’s stock.

About NxStage Medical

NxStage Medical, Inc is a medical technology company. The Company is engaged in the development, manufacturing and marketing of products and services for patients suffering from chronic or acute kidney failure. The Company operates through three segments: System One, In-Center and Services. It offers its products and services to various markets, such as home, critical care and in-center.

5 Day Chart for NASDAQ:NXTM

Receive News & Stock Ratings for NxStage Medical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NxStage Medical Inc. and related stocks with our FREE daily email newsletter.